Press Release

KPI Therapeutics Will Present New, Positive Data on KPI-150 as a Potential New Therapy for Atopic Dermatitis at Upcoming Skin Disease Conference

New data demonstrates preclinical efficacy including skin penetration

Download PDF

SEATTLE, Feb. 28, 2017 – KPI Therapeutics Inc., a clinical stage biotechnology company today announced it has been invited to present new, updated data on its KPI-150 program, a topical Kv1.3 inhibitor, as a potential new therapy against atopic dermatitis at the Society for Investigative Dermatology 76th Annual Meeting in Portland OR, April 26-29. KPI's Vice-President, Scientific Affairs, Chelsea Olsen, Ph.D. will present data showing that KPI-150 is effective against atopic dermatitis in animal models when applied topically including new skin penetration data. KPI-150 may also be effective against other dermatologic inflammatory diseases. Fifteen million Americans suffer from atopic dermatitis. Treatment options for this disease are limited, and long-term management solutions are lacking. KPI-150 is a new treatment modality with a novel mechanism of action that is not associated with the broad immunosuppression of existing agents.

About KPI Therapeutics

KPI Therapeutics is a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children's Therapeutics, which includes Seattle Children's Research Institute. For more information about KPI please visit our website: www.kpitherapeutics.com

About KPI-150, KPI-190, and dalazatide

KPI-150 is a novel Kv1.3 inhibitor from the same family of molecules in KPI Therapeutics' autoimmune platform which includes KPI-190 and dalazatide. Preclinical and clinical data have shown that these drugs are selective and potent blockers of the voltage-gated Kv1.3 potassium channel - a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. KPI-150 is in development for atopic dermatitis (also commonly referred to as eczema) a medical condition of the skin associated with severe itching, redness, scaling, and flaking. About half of all atopic dermatitis sufferers are under the age of 18. In both children and in adults, this disease is associated with sleep disturbances, more days of lost work or school, and an adverse quality of life.

KPI-190 is also a novel Kv1.3 inhibitor in development as a therapy for eye diseases such as dry eye syndrome and uveitis which can cause irreversible vision damage. Uveitis is one of the leading causes of blindness in the US and remains a significant unmet need. There are over 680,000 uveitis patients in the US with few treatment options. More than thirteen million people a year in the US are affected by Dry Eye disease.

Dalazatide, is a potential new therapy for systemic autoimmune diseases. It has completed a Phase 1b clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA) as in KPI-150 and KPI-190. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. It is Phase 2 ready. Dalazatide is being studied as a treatment for multiple autoimmune diseases including lupus, myositis, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI's plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Us